The cephalosporin antibiotics were first made available for clinical use with the introduction in 1964 of cephalothin and cephaloridine. They have subsequently proved very effective in the treatment of infections, including serious life-threatening infections, in man. The first introductions were followed by others, including cephalexin and cephradine (both orally absorbed) cephapirin and cefazolin. All of these substances, whether orally absorbed or for administration by injection, have some shortcomings, most of them minor. However, the one feature in common is that they are all, to a greater or lesser extent, susceptible to breakdown and inactivation by ,B-lactamases from Gram negative organisms. An awareness has thus grown up of a need for a cephalosporin with substantial resistance to these enzymes and one which might also overcome some of the other disadvantages of the various individual members of the 'first generation' cephalosporins.
Since 1964, knowledge of structure-activity relationships in the cephalosporins has increased considerably so that, while a new compound with desirable properties cannot yet be designed entirely on paper, some obvious pitfalls can now be avoided. The knowledge, moreover, has made it obvious that some desirable features seem to be mutually exclusive, so that although one would like to discover the ultimate in antibiotic compounds, with all the advantages and no disadvantages, it seems unlikely (certainly on present knowledge) that such a substance can be found among the cephalosporins and related substances. The short answer to the question why cefuioxime? is that of the structures under investigation at the time that the choice was made, cefuroxime seemed to be the best 'all round' substance, with most of the advantages that we sought without the disadvantages being too great. To make these points clear it is better to consider them one by one.
Injectable versus Oral
There are obvious advantages in being able to give antibiotics by mouth, especially from the patient's point of view. Nevertheless, the available oral cephalosporins, cephalexin and cephradine, fulfil most of the requirements for an oral cephalosporin by being effective, very well absorbed from the gastrointestinal tract and very well tolerated. Their lack of activity against 3-lactamase producing Gram negative organisms is of less importance since they tend to be used for important, but not immediately life-threatening infections.
The injectable cephalosporins, on the other hand, tend to be used more in hospitals or in specialized practice for the treatment of lifethreatening infections where the breadth of spectrum to include most ,B-lactamase producers is more important. Our research was therefore directed more towards structures that gave the I at SAGE Publications on June 21, 2016 jrs.sagepub.com Downloaded from required activity and the stability that we sought, rather than to structures which tend to be orally absorbed. Thus, cefuroxime, at least in its present form, is intended for administration by injection only.
As the sodium salt, it has a relatively low pain factor on intramuscular injection and the standard 750 mg injection can be given repeatedly by this route without the need to administer it with novocaine. ft can, of course, be given by other routes of injection especially intravenously, a route favoured when injections requiring higher doses are to be given.
Antibacterial Spectrum
Like all cephalosporins, cefuroxime is highly resistant to staphylococcal penicillinase and thus its high activity against Staphylococcus aureus is maintained whether the strain produces penicillinase or not. The only exceptions to this are the so-called methicillin resistant strains. The mode of action of cefuroxime (inhibition of transpeptidase and carboxypeptidase enzymes involved in cell wall biosynthesis) is similar to that of other P-lactam antibiotics and it will not cause the inhibition of bacterial cells which are naturally deficient in cell wall. The Pneumococci and Streptococci, with the exception of most strains of Streptococcus faecalis, are very sensitive to cefuroxime.
Turning to the Gram negative organisms, cefuroxime is active against all organisms that are sensitive to cephalothin or cephaloridine plus a large proportion of those organisms (Escherichia coli, Proteus, Klebsiella and Enterobacter spp) which produce f-lactamases. In addition, the Neisseriae, including N. gonorrhaea and N. meningitidis are extremely sensitive as also are strains of Hamophilus influenza?. It is among these last organisms that we have seen examples of the advantage of cefuroxime's resistance to R-factor mediated /3-lactamases. Strains of N. gonnorrhaa, of H. influenza, and N. catarrhalis can acquire a high degree of resistance to the penicillins and to first generation cephalosporins by such a 3actamase, but nevertheless remain fully sensitive to cefuroxime.
Some Gram negative organisms are not sensitive to cefuroxime, usually because they produce a ,B-lactamase to which the antibiotic is susceptible. Some strains of Proteus spp. and some strains of Aerobacter spp. which produce Class I /3-lactamase are not sensitive, but, in surveys of organisms causing infections in patients, they are relatively few in number. All but a very few, rare strains of Pseudomonias aeruginosa are resistant to cefuroxime. A permeability barrier problem is probably involved with these organisms. Some strains of Bacteroides fragilis are resistant to cefuroxime and other forms of treatment would be indicated as well as, or instead of, cefuroxime if the presence of that organism were suspected.
However, the spectrum of antibacterial activity is very wide, and it includes a high activity against organisms that are essentially unaffected by other cephalosporins.
Toxicity Considerations
Like the penicillins, the cephalosporins in general are of low toxicity. However, at very high dose levels, most members of the first generation of injectable cephalosporins can be shown to have some nephrotoxic action in laboratory animals, while various nephropathies occurring in human subjects under treatment (usually while some other nephrotoxic drug was being administered concurrently) have been attributed to the cephalosporin.
An early specification for a new second generation cephalosporin therefore, was that it should have a very low toxicity and that it should have a wide safety margin at the dose levels recommended for treatment in human beings. The toxicity of cefuroxime is being dealt with in another paper at this Conference by Dr Foord and his co-workers. Suffice to say that the toxicity as measured in laboratory animals is very low and will permit concurrent treatment with other antibiotics such as gentamicin, should this be indicated.
Another factor, the importance of which has only lately been fully realized, is the potential of a /3-lactam antibiotic to induce hypersensitivity reactions in those individuals repeatedly injected with the substance. In general, the cephalosporins have had a good record in this respect and many of those with a frank hypersensitivity to penicillins have been treated without event by a cephalosporin. Cephalexin has a particularly good clinical record in this respect. Laboratory techniques for investigating the sensitizing potential of antibiotics, particularly /-lactam antibiotics, are now established and the sensitizing potential of new compounds can be investigated before they are given to human beings. Some cephalosporins, including some of the oxime series, undergo a form of destructive binding with human serum albumin. We fear that destructive binding of this kind might provoke sensitization reactions in man. Cefuroxime is not destructively bound in this way and, perhaps in consequence, its sensitizing potential as measured in laboratory animals is very low. This work will form the basis of a publication elsewhere.
Pharmacokinietics
However active an antibiotic in vitro, its effectiveness in treating human infections will be limited Cefuroxime unless the delivery system to the infected site is good. In a later paper, Dr O'Callaghan and Dr Harding will be describing the pharmacokinetic properties of cefuroxime as measured in human subjects and will be relating these to the antimicrobial activity of the substance against relevant pathogenic organisms.
The limitations placed on the target for the research that led to cefuroxime were that the substance should give high serum levels, preferably not be serum protein bound, that the rate of elimination by the kidney should be not too great and that the material in the human body would remain unchanged (i.e. not metabolized) and thus fully maintain its antimicrobial activity.
All of these requirements have been met.
Antibiotic Qutality
We have recently become aware that the modes of action of all ,-lactam antibiotics are not exactly the same. This may be due to a number of factors including resistance to inactivating intracellular enzymes (f3-lactamases), the rate of bacterial cell penetrability and the pattern of binding to the bacterial target enzyme system (transpeptidases, particularly). We believe especially that the penetrability of the antibiotic into the bacterial cells should be at a sufficient rate, otherwise the target enzymes within the cell are not subjected to the full concentration of antibiotic at the peak of the tissue level curves.
It appears that in all of these respects, cefuroxime has favourable properties. Studies in our laboratories have shown that its ability to penetrate cells (e.g. E. coli) is almost the same as cephaloridine, a cephalosporin with an exceedingly good potential for entry. Its very low susceptibility to most ,3-lactamases combined with this property means a high degree of antibacterial effectiveness. Studies on laboratory animals have confirmed that cefuroxime has a good protective activity in a number of animal models with a range of infecting organisms.
Discussiont
Why Cefuro.rime? This question was asked at the stage in the research on the compound when the properties outlined above were beginning to emerge and when data on other compounds were also being accumulated which suggested that they too might have potential as useful injectable broad spectrum compounds. The answer was that cefuroxime had the best all round properties. It had few deficiencies in its antibacterial spectrum and these were to some extent filled by already available compounds.
Moreover, the gaps tended to be with organisms (e.g. Pseudomonas aruginosa, Bacteroides fragilis, Streptococcus facalis) which are only rarely the cause of life-threatening infections. In contrast, organisms associated with severe respiratory tract infections, with septicemias, with meningitis and with many serious wound infections would be readily treated with cefuroxime. Organisms which pick up an R factor specifying /3-lactamase production, and which thereby acquire resistance to other /3-lactam antibiotics remain sensitive to cefuroxime. The bonus of very high activity against N. gonorrha'(e is also notweorthy. These factors, combined with a low toxicity and very favourable pharmacokinetic properties finally led to the choice of this substance. We feel it will find an acceptable place in the armamentarium against serious infections in man and that its properties may make it a superior alternative to all the first generation cephalosporins at present in use.
During this meeting, many of the properties of the substance will be dealt with in detail, and many clinical experiences will be described. We therefore await an endorsement that our choice of cefuroxime was a correct one.
